<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695448</url>
  </required_header>
  <id_info>
    <org_study_id>PIK111051</org_study_id>
    <nct_id>NCT00695448</nct_id>
  </id_info>
  <brief_title>Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2&#xD;
      dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated prematurely due to lack of sufficient exposure following single- and&#xD;
    repeat-dosing.&#xD;
  </why_stopped>
  <start_date type="Actual">June 24, 2008</start_date>
  <completion_date type="Actual">March 31, 2009</completion_date>
  <primary_completion_date type="Actual">March 31, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs) and changes in laboratory values and vital signs as per protocol.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter values for GSK1059615 following single and repeated dosing, including area under the plasma drug concentration curve (AUC), maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to maximum observed plasma drug concentration, and half-life of GSK1059615.</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic profiling in plasma and urine, and amount excreted in urine (subset of patients).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as defined by RECIST in the protocol.</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in protein markers in tumor and/or blood.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose and insulin levels.</measure>
    <time_frame>Daily for 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1059615</intervention_name>
    <description>GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.</description>
    <arm_group_label>Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  18 years old or older.&#xD;
&#xD;
          -  Histologically- or cytologically- confirmed diagnosis of solid tumor malignancy or&#xD;
             lymphoma that is not responsive to accepted standard therapies or for which there is&#xD;
             no standard or curative therapy.&#xD;
&#xD;
          -  Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale.&#xD;
&#xD;
          -  A life expectancy of &gt; 12 weeks.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  A male is eligible to enter and participate in the study if he either:&#xD;
&#xD;
          -  agrees to abstain from sexual intercourse from the first dose of study drug and until&#xD;
             21 days after last dose of study medication, or&#xD;
&#xD;
          -  agrees to use a condom and occlusive cap (diaphragm or cervical/vault cap) with&#xD;
             spermicidal foam/gel/film/cream/suppository from the first dose of study drug and&#xD;
             until 21 days after last dose of study medication, or&#xD;
&#xD;
          -  is surgically sterile. NOTE: Male patients must use contraception to prevent pregnancy&#xD;
             in a female partner and prevent exposure of any partner to semen by any means (refer&#xD;
             to protocol).&#xD;
&#xD;
          -  A female is eligible to enroll in the study if she is of:&#xD;
&#xD;
        Non-child bearing potential (i.e., physiologically incapable of becoming pregnant)&#xD;
        including any woman who is characterized by at least one of the following:&#xD;
&#xD;
          -  Has had a hysterectomy&#xD;
&#xD;
          -  Has had a bilateral oophorectomy (ovariectomy)&#xD;
&#xD;
          -  Has had a bilateral tubal ligation&#xD;
&#xD;
          -  Is post-menopausal (total cessation of menses for ≥ 1 year) Childbearing potential,&#xD;
             has a negative serum pregnancy test at screening, and agrees to one of the following&#xD;
             from at least 2 weeks prior to the first dose of study drug and until 21 days after&#xD;
             last dose of study medication:&#xD;
&#xD;
          -  Use an intrauterine device (IUD) with a documented failure rate of&#xD;
&#xD;
          -  less than 1% per year.&#xD;
&#xD;
          -  Have intercourse only with a vasectomized partner who is sterile&#xD;
&#xD;
          -  and is the sole sexual partner for that woman.&#xD;
&#xD;
          -  Complete abstinence from sexual intercourse.&#xD;
&#xD;
          -  Use double barrier contraception defined as condom with&#xD;
&#xD;
          -  spermicidal jelly, foam, suppository, or film; OR diaphragm with&#xD;
&#xD;
          -  spermicide; OR male condom and diaphragm. NOTE: Oral contraceptives are not reliable&#xD;
             due to potential for drug-drug interaction.&#xD;
&#xD;
          -  Adequate organ system function as defined in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of an investigational anti-cancer drug within 28 days or 5 half-lives preceding&#xD;
             the first dose of GSK1059615.&#xD;
&#xD;
          -  Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C).&#xD;
             Chemotherapy regimens given continuously or on a weekly basis with limited potential&#xD;
             for delayed toxicity are permitted with approval of the GSK medical monitor if&#xD;
             administered at least 2 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  Trastuzumab within the last 4 weeks.&#xD;
&#xD;
          -  Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks.&#xD;
&#xD;
          -  Prior use of any PI3K inhibitor.&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to the study drug. (To date there are no known FDA approved drugs&#xD;
             chemically related to GSK1059615).&#xD;
&#xD;
          -  Current use of a prohibited medication or requires any of these medications during&#xD;
             treatment with GSK1059615 as per protocol.&#xD;
&#xD;
          -  Current use of warfarin for therapeutic anticoagulation.&#xD;
&#xD;
          -  NOTE: Low molecular weight heparin and prophylactic low-dose warfarin are permitted.&#xD;
             PT/PTT must meet the inclusion criteria. Patients taking warfarin must have their INR&#xD;
             followed closely.&#xD;
&#xD;
          -  Presence of an active gastrointestinal disease or other condition known to interfere&#xD;
             significantly with the absorption, distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          -  Unresolved toxicity greater than Grade 1 from previous anti-cancer therapy except&#xD;
             alopecia. Patients with stable Grade 2 neuropathy can be enrolled with approval by the&#xD;
             GSK Medical Monitor.&#xD;
&#xD;
          -  QTc interval ≥ 480 msecs.&#xD;
&#xD;
          -  History of acute coronary syndromes (including unstable angina and myocardial&#xD;
             infarction), atrial fibrillation, coronary angioplasty, or stenting within the past 24&#xD;
             weeks.&#xD;
&#xD;
          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system.&#xD;
&#xD;
          -  Symptomatic or untreated leptomeningeal or brain metastases. Patients previously&#xD;
             treated for these conditions who are asymptomatic and off of corticosteroid and&#xD;
             P450-inducing anti-epileptic medication for at least 2 months are permitted.&#xD;
&#xD;
          -  Primary malignancy of the central nervous system.&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol.&#xD;
&#xD;
          -  Concurrent condition that in the investigator's opinion would jeopardize compliance&#xD;
             with the protocol.&#xD;
&#xD;
          -  Nursing female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>July 23, 2017</last_update_submitted>
  <last_update_submitted_qc>July 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphoinositide 3-kinase inhibitor</keyword>
  <keyword>solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PIK111051</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

